Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987510 | 0.92 | NR1H2 (0.50) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22987660 | 0.89 | POLB (0.48) | ADORA3ADORA2AADORA1XDHMAPT | |
| SCHEMBL22988097 | 0.88 | PDPK1 (0.40) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22987505 | 0.85 | NR1H2 (0.41) | NR1H2NR1H3MAPT | |
| SCHEMBL22987675 | 0.83 | EGFR (0.38) | NR1H2NR1H3ADORA3ADORA2AXDH | |
| SCHEMBL29646424 | 0.83 | ADORA3 (0.38) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22978982 | 0.83 | ADORA3 (0.38) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22987774 | 0.81 | ADORA3 (0.45) | ADORA3ADORA2AADORA1XDHMAPT | |
| SCHEMBL30393569 | 0.81 | ADORA3 (0.45) | ADORA3ADORA2AADORA1XDHMAPT | |
| SCHEMBL22987757 | 0.81 | ADORA2A (0.38) | NR1H2NR1H3ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | NR1H2 296/4885NR1H3 422/4885ADORA3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.